← 홈

혈액암 (AML/ALL) · VEGF

37개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 37개
CGTBiologicstaleRochePhase 2

NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy (NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy)

NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer · NSCLC (Advanced Non-small Cell Lung Canc

#NSCLCAdvancedNon-smallCellLungCa#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleRocheApproved

bevacizumab + oxaliplatin + capecitabine (Pabolizumab+ bevacizumab and CapeOX, Pabolizumab+ bevacizumab and CapeOX (bevacizumab + oxaliplatin + capecitabine))

Locally Advanced Colorectal Cancer · Locally Advanced Colorectal Cancer

#LocallyAdvancedColorectalCancer#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab plus Bevacizumab)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 56.3%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Olaparib; Bevacizumab (QLS5132; Olaparib; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Centre, Singapo…Phase 2

atezolizumab (Tecentriq, SIRT-Y90 with Atezolizumab + Bevacizumab)

Locally Advanced Hepatocellular Carcinoma · Locally Advanced Hepatocellular Carcinom

#LocallyAdvancedHepatocellularCar#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Serplulimab combined with bevacizumab and first-line chemotherapy (Serplulimab combined with bevacizumab and first-line chemotherapy)

Non-small Cell Lung Cancer Stage II; Bevacizumab · Non-small Cell Lung Cancer Stage II

#Non-smallCellLungCancerStageII#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Targeted therapy with bevacizumab (Targeted therapy with bevacizumab)

Locally Advanced Rectal Cancer (LARC) · Locally Advanced Rectal Cancer (LARC)

#LocallyAdvancedRectalCancerLARC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePreclinical

bevacizumab plus nab-paclitaxel and platinum (bevacizumab plus nab-paclitaxel and platinum)

Non-small Cell Lung Cancer Metastatic · Non-small Cell Lung Cancer Metastatic

#Non-smallCellLungCancerMetastati#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 1

bevacizumab with chemotherapy, Pleur-XTM catheter placement (bevacizumab with chemotherapy, Pleur-XTM catheter placement)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

bevacizumab, carboplatin and paclitaxel (bevacizumab, carboplatin and paclitaxel)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJohnson & Johnson Pharmaceutica…Phase 2

doxorubicin HCL liposome; bevacizumab; carboplatin (doxorubicin HCL liposome; bevacizumab; carboplatin)

Ovarian Neoplasms; Fallopian Tube Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleMt. Sinai Medical Center, MiamiPhase 2

oxaliplatin, gemcitabine, bevacizumab (oxaliplatin, gemcitabine, bevacizumab)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSpanish Lung Cancer GroupPreclinical

paclitaxel, carboplatin and bevacizumab (paclitaxel, carboplatin and bevacizumab)

Nonsquamous Nonsmall Cell Neoplasm of Lung · Nonsquamous Nonsmall Cell Neoplasm of Lu

#NonsquamousNonsmallCellNeoplasmo#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE

2 / 2 페이지

← 이전다음 →